donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > ZYME Zymeworks > Detailed Quotes

ZYME Zymeworks

7.000
+0.510+7.86%
Close 08/08 16:00 ET
7.00000.00%
Post Mkt Price 08/08 16:32 ET
High
7.290
Open
6.500
Turnover
16.41M
Low
6.500
Pre Close
6.490
Volume
2.34M
Market Cap
405.25M
P/E(TTM)
Loss
52wk High
37.190
Shares
57.89M
P/E(Static)
Loss
52wk Low
4.560
Float Cap
302.07M
Bid/Ask %
-71.43%
Historical High
59.030
Shs Float
43.15M
Volume Ratio
2.25
Historical Low
4.560
Dividend TTM
--
Div Yield TTM
100
P/B
1.82
Dividend LFY
--
Div Yield LFY
1428.57%
Turnover Ratio
5.42%
Amplitude
12.17%
Avg Price
7.008
Lot Size
1
Float Cap
302.07M
Bid/Ask %
-71.43%
Historical High
59.030
Shs Float
43.15M
Volume Ratio
2.25
Historical Low
4.560
Dividend TTM
--
P/B
1.82
Dividend LFY
--
Turnover Ratio
5.42%
Amplitude
12.17%
Avg Price
7.008
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
CEO: Galbraith C.A., Kenneth H.
Market: NYSE
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...